Mucositis

Subscribe to Selected New Research on Mucositis

1484 relevant articles (120 outcomes, 235 trials/studies) found for this Disease

Description: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).

Also Known As:

Mucositides

Relationship Network

Disease Context: Research Results

Digestive System Diseases: 29

Gastrointestinal Diseases: 1158

Gastroenteritis: 1701

Mucositis: 1484

Stomatognathic Diseases: 250

Mouth Diseases: 55

Mucositis: 1484

Related Diseases

1.	Neoplasms (Cancer)
2.	Head and Neck Neoplasms (Head and Neck Cancer)
3.	Pain (Aches)
4.	Neutropenia
5.	Vomiting

Experts

1.	Gibson, Rachel J: 9 articles (06/2008 - 07/2002)
2.	Keefe, Dorothy M K: 8 articles (06/2008 - 07/2002)
3.	Bowen, Joanne M: 7 articles (09/2008 - 07/2006)
4.	Butler, Ross N: 7 articles (02/2008 - 02/2005)
5.	Sonis, Stephen T: 6 articles (09/2008 - 08/2004)
6.	Howarth, Gordon S: 6 articles (02/2008 - 02/2005)
7.	Tooley, Katie L: 5 articles (02/2008 - 06/2006)
8.	Logan, Richard M: 4 articles (06/2008 - 04/2007)
9.	Stringer, Andrea M: 4 articles (06/2008 - 04/2007)
10.	Pieters, Rob: 4 articles (08/2007 - 06/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mucositis:

1.	Amifostine (Ethyol)FDA LinkGeneric 07/01/2000 - "The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0" 06/01/2000 - "A significant reduction of pharyngeal, esophageal, and rectal mucositis was noted in the amifostine arm (P <.04)" 06/01/1986 - "We have previously reported that Amifostine, a radioprotective agent, was effective in treating acute radiation mucositis in the head and neck region" 01/01/2002 - "The authors have developed a rat RT model to examine the protective effects of amifostine after IV and subcutaneous (SC) administration in a mucositis model" 03/01/2002 - "Ongoing trials are being conducted to determine the efficacy of amifostine in reducing radiation-induced mucositis and other toxicities" Order ALL the reference details at left...
2.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/01/2005 - "BACKGROUND: Previous studies suggested granulocyte-macrophage-colony stimulating factor (GM-CSF) might be beneficial for radiotherapy-induced mucositis" 01/01/2005 - "Forty-five percent of the patients randomized to receive GM-CSF had a significant reduction of the mucositis more than one grade compared to 9% of the conventional treated" 01/01/2005 - "CONCLUSIONS: In severe mucositis, GM-CSF is more effective than conventional treatment." 03/01/2006 - "The present study was performed to investigate the protective effects of granulocyte macrophage-colony stimulating factor (GM-CSF) against ulcerative mucositis in hamster buccal pouch" 01/01/2005 - "This trial examined the efficacy of GM-CSF in reducing mucositis of the oral cavity and/or oropharynx compared with conventional treatment" Order ALL the reference details at left...
3.	Sucralfate (Carafate)FDA LinkGeneric 01/01/1999 - "Sucralfate mouth washing is beneficial in decreasing the intensity of radiation-induced mucositis and oral discomfort" 07/01/2001 - "In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments" 01/01/1995 - "RESULTS: There is increasing evidence that sucralfate reduces the severity of radiation-induced mucositis in the head and neck, esophagus, and the lower gastrointestinal tract" 01/01/2003 - "Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial." 03/01/1997 - "RESULTS: There was a total of 131 assessable patients entered onto this trial, 50 of whom developed mucositis and used the study medication (27 sucralfate and 23 placebo)" Order ALL the reference details at left...
4.	Fluorouracil (Carac)FDA LinkGeneric 02/01/2008 - "In this study, we investigated the effects of an Eriobotrya japonica seed extract (ESE) on mucositis using a 5-fluorouracil (5-FU)-induced mucositis hamster model" 02/01/2000 - "The MTD and recommended dose for phase II clinical trials of GEM and 5-FU on the above schedule is 1,000 mg/m2 and 200 mg/m2 respectively, with mucositis as the DLT." 04/01/1988 - "The maximally tolerated dose of 5-FU in this study was 800 mg/m2/d, with mucositis in previously irradiated sites being dose-limiting" 01/01/1984 - "Mucositis and myelosuppression were dose-limiting, with recommended dose levels of 5FU for further trials being 10 mg/kg/d I.V. d1-5 and 1000 mg/m2/d I.V. d1-4 on the bolus and continuous infusion schedules, respectively" 12/01/2008 - "AIM: To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis" Order ALL the reference details at left...
5.	Cisplatin (Platino)FDA LinkGeneric 02/01/1994 - "Severe and worse toxic events were similar between the treatment programs, but radiation-induced mucositis combined with cisplatin-induced water-losing nephropathy, in the concomitant arm only, demanded more supportive care" 04/01/2007 - "CONCLUSIONS: Although therapeutics results are equivalent to cisplatin schemes of concurrent CT-RT, mucositis and cutaneous toxicity registered in this trial must be considered as limiting factors to application of this new approach." 08/01/2004 - "Toxicities of cisplatin chemoradiotherapy consisted of grade 3 or 4 mucositis (79%) and neutropenia (51%)" 11/01/2005 - "Six patients in Phase I defined the MTD for concurrent PF as: cisplatin 10 mg/m2/day and PF 320 mg/m2/day, on Days 1-5 during Weeks 6 and 7 of radiation therapy based on dose-limiting toxicities of mucositis, neutropenia, and thrombocytopenia" 01/01/1994 - "The total dose of cis-platinum was 140 mg and that of radiation was 70 Gy. Moderate leukocytopenia and moderate mucositis/dermatitis were observed as side effects, but despite the lack of intravenous hydration no signs of renal toxicity were observed" Order ALL the reference details at left...
6.	Allopurinol (Remid)FDA LinkGeneric 01/15/1983 - "Allopurinol did not produce a significant degree of protection against 5-FU-induced myelosuppression or mucositis on either dose schedule" 09/01/2005 - "Mucositis was rare with allopurinol protection" 04/15/1990 - "These data demonstrate that the tested allopurinol mouthwash regimen does not offer any protective effect against 5-FU-induced mucositis." 04/15/1990 - "There was trend toward less mucositis in the placebo group with mean physician-judged mucositis scores of 1.3 for placebo and 1.8 for allopurinol (P = 0.07) and mean patient-judged mucositis scores of 1.5 for placebo and 1.9 for allopurinol (P = 0.15)" 01/01/1990 - "Early pilot studies suggested that an allopurinol mouthwash could lessen 5-FU-induced mucositis" Order ALL the reference details at left...
7.	ChlorhexidineIBA 05/01/2004 - "According to this sequential analysis, the study could be terminated at the 34th within subject comparison, with a statistically significant reduction in ulcerative lesions (P<0.05) and severity of mucositis (P<0.05) in children on the chlorhexidine protocol" 12/01/1994 - "Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis." 09/01/2006 - "In the chlorhexidine arm, 4 subjects (57%) had grade 2, and 3 subjects (43%) had grade 3 mucositis" 04/01/2003 - "Seven of 15 patients developed severe mucositis in the chlorhexidine-based group, but only two of 15 patients in the control group" 04/01/2003 - "Nine patients in the chlorhexidine-based group but only two patients in the control group developed severe mucositis" Order ALL the reference details at left...
8.	Fibroblast Growth Factor 7 (Palifermin)FDA Link 05/20/2008 - "Future studies should evaluate higher palifermin doses with longer and more standardized assessment of acute mucositis." 07/01/2007 - "In clinical trials, palifermin, a recombinant humanized keratinocyte growth factor (rHuKGF), has demonstrated an ability to decrease the incidence and duration of mucositis" 08/01/2002 - "Cell kinetic studies in the murine ventral tongue epithelium: mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF)." 04/01/1999 - "Mucositis could be influenced by new keratinocyte growth factor (KGF), which is now in phase I trials." 09/01/2008 - "The duration of mucositits in patients who acquired a higher grade mucositis despite treatment with palifermin could be reduced from 12.9 days (median) without to 11 days with palifermin" Order ALL the reference details at left...
9.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/01/2006 - "Granulocyte colony stimulating factor for mucositis during post-operative radiotherapy." 03/01/2001 - "Patients receiving G-CSF had less grade III-IV mucositis than those who did not receive G-CSF (P = 0.01)" 03/01/1999 - "Our observations indicate that G-CSF did not appear to have influenced the objective mucositis although it reduced the number of treatment breaks" 07/15/1997 - "Grade 3/4 mucositis, observed in 65% of patients, was equally prevalent and prolonged in both G-CSF-treated (+) and G-CSF-naive (-) patients" 11/01/1994 - "G-CSF allowed for escalation of HU to 1 g orally every 12 hours without dose-limiting acute toxicity during cycles 1 and 2. Dose-limiting cumulative toxicity consisted of severe or life-threatening myelosuppression and mucositis" Order ALL the reference details at left...
10.	Benzydamine (Tantum)IBA 01/01/1985 - "A double-blind, randomized clinical study was undertaken to determine the analgesic and antiinflammatory effectiveness of benzydamine in patients with radiation-induced mucositis of the oropharynx" 01/01/1985 - "A clinical study of benzydamine for the treatment of radiotherapy-induced mucositis of the oropharynx." 09/01/2006 - "In the benzydamine arm, 5 subjects (71%) had grade 2, and 2 subjects (29%) had grade 3 mucositis (P > .05)" 12/01/2003 - "CONCLUSIONS: Of the current available products, ice chips and benzydamine have the strongest scientific evidence of support for prophylaxis of mucositis." 04/01/1986 - "Analysis of the data showed that benzydamine HCl used as a rinse/gargle provided a statistically significant and clinically meaningful alleviation of the symptoms of oropharyngeal mucositis" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 10/01/2002 - "Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown." 02/01/1999 - "In the Gln group, a significant reduction in mucositis and ulcerations of the gastric (P < 0.01) and duodenal mucosa (P < 0.05) was documented after the third course of chemotherapy" 08/01/2003 - "Aiming to reduce crypt cell apoptotic sensitivity to cytotoxic chemotherapy and/or to enhance crypt epithelial proliferative repair, several exogenous growth factor treatments have been tested, either preclinically and/or clinically, and are showing promise for their efficacy or safety in preventing or treating chemotherapy-induced mucositis" 01/01/1999 - "Phase I/II studies to evaluate the safety and efficacy of rHuKGF in the prevention of chemotherapy-induced mucositis are currently in progress." 07/01/1997 - "Early studies suggested improved healing, as do recent studies of small intestinal mucositis resulting from chemotherapy" Order ALL the reference details at left...
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 05/01/1994 - "Transient mucositis occurs in almost all patients receiving bone marrow transplantation (BMT) but it is not known whether airway mucociliary transport is impaired during this period" 11/01/1990 - "A system for assessing the severity of mucositis in patients undergoing bone marrow transplantation (BMT) is presented" 05/01/2004 - "The purpose of this article is to review the current research studies on the prevention and treatment of oropharyngeal mucositis following chemotherapy, radiotherapy, and bone marrow transplantation with an emphasis on biomedical, oral symptomatic, and functional impairment outcomes" 09/01/2004 - "Similarly, patients who undergo bone marrow transplantation and who receive high doses of chemotherapy have a 76% chance of getting mucositis" 07/01/2001 - "Mucositis is still a leading side effect of high dose chemotherapy and irradiation delivered in autologous and allogeneic bone marrow transplantation" Order ALL the reference details at left...
3.	Oral Hygiene (Dental Hygiene) 11/01/1985 - "A nonbrushing method of oral hygiene was effective in reducing the severity and duration of mucositis" 11/01/2006 - "CONCLUSIONS: In our study, a good gingival status as well as good oral hygiene during chemoradiotherapy is associated with a lower incidence and severity of mucositis." 11/01/2006 - "A descriptive study was made, analyzing oral hygiene, one dental index, and two gingivales indices, and evaluating their relationship with the appearance of mucositis" 01/01/1999 - "The purposes of this study were to determine if there were differences in the incidence, severity, and time to onset of CTX-induced mucositis in oncology outpatients who wore dental appliances, had a history of oral lesions, had varying oral hygiene/care practices, and had a history of smoking and those who did not" 01/01/2000 - "Basic requirements in prevention and control of mucositis are good oral hygiene, mechanical débridement of the oral tissues, and hydration." Order ALL the reference details at left...
4.	Transplants (Transplant) 12/01/1990 - "In this study, 60 patients who received BMTs were evaluated for at least 30 days post-transplant for ulcerative mucositis and the presence of culturable HSV" 10/01/2008 - "The use of MTX for GVHD prophylaxis may be associated with significant toxicity, including hepatotoxicity, graft failure and mucositis" 06/01/2007 - "Plasma cell mucositis in a lung transplant patient." 01/01/2007 - "Radiation therapy to the head and neck, as well as stem cell transplant conditioning regimens, have the highest incidence of severe mucositis" 12/01/2006 - "Time to engraftment, severity of mucositis and transplant duration were identical for the two groups" Order ALL the reference details at left...
5.	Patient-Controlled Analgesia (Analgesia, Patient Controlled) 09/01/1998 - "Patient-controlled analgesia (PCA) systems have been reported to be of benefit in controlling BMT-associated mucositis" 09/01/1991 - "Adolescents use patient-controlled analgesia effectively for relief from prolonged oropharyngeal mucositis pain." 08/01/2006 - "However, a small group, such as those presenting severe mucositis or requiring a rapid pain relief, should be managed by intravenous continuous infusion and/or by a patient-controlled analgesia system; while for patients in the community, there are distinct advantages to using the subcutaneous route" 09/01/1998 - "Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis." 09/01/1991 - "We compared patient-controlled analgesia (PCA) and continuous infusion (CI) morphine delivery in a randomized controlled trial in adolescents during oropharyngeal mucositis pain after bone marrow transplantation" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Mucositis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 120 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>